Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy

Research on psychedelic-assisted psychotherapy for cancer-related psychological and existential distress dates back to the 1960s–1970s and included several hundred participants, with reports of improvements in depression, anxiety, fear of dying, quality of life and pain. More recent controlled trials of psilocybin have likewise reported rapid, substantial and sustained reductions in cancer-related anxiety and depression, reductions in existential distress, and changes in orientation toward death. In-depth qualitative work from one such trial identified common experiential themes across participants, but left open questions about the individualized content and clinical courses of treatment responses. Ross and colleagues set out to illustrate the personalised, idiographic aspects of psilocybin-assisted psychotherapy by presenting four case reports drawn from that larger double-blind randomised trial. The aim was to show how distinct subjective experiences map onto clinical change, and to use combined quantitative and qualitative material to highlight psychological processes that could inform future trial design, measures and hypotheses.

The material reported here derives from a completed double-blind randomised controlled trial of psilocybin-assisted psychotherapy for anxiety and depression in cancer patients; the present paper draws on that trial plus two qualitative analyses of interview data from a subset of participants. The authors combined quantitative measures (reported elsewhere and referenced in Supplementary Materials) with qualitative source material including semi-structured interviews, participant-written narratives, and therapists' clinical notes. Demographic identifiers were obscured to preserve anonymity, and each of the four individuals whose experiences are presented gave written informed consent for publication of de-identified case material. Participants for these four case reports were purposively selected to illustrate a range of themes that emerged in the larger qualitative work and because each benefited from treatment in different ways. The extracted text does not clearly report the overall trial sample size, dosing regimen, specific psychotherapeutic procedures in full detail, or the precise statistical analysis plan for the main trial within this section; readers are referred to the Supplementary Materials cited by the authors for quantitative measure descriptions and trial overview. The case-report method was chosen to bridge controlled-trial outcomes and qualitative description, enabling idiographic exploration of participants' subjective experiences alongside standardised outcome measures.

The authors state that quantitative clinical anxiety and depression results, demographic information, and measures of demoralisation, hopelessness and attitudes toward death are presented in figures and tables referenced in the paper; the extracted text does not include those figures or the full numeric results. They report that each of the four participants described showed improvement on multiple outcome measures regardless of the particular content of their psilocybin session. Victor: A male in his 20s who had been treated for non-Hodgkin's lymphoma and was in remission, Victor presented with severe anxiety, intermittent panic attacks and constant worry about recurrence and was diagnosed with Adjustment Disorder with Anxiety, Chronic. During his session he experienced closed‑eye visuals and a guided journey led by a felt "spirit guide," witnessing conception, birth and death, and a process of reintegration with his body that he described as acceptance. He encountered a divine figure and later a reassuring image of his father, and saw deceased loved ones expressing love. The extract indicates clinical improvement across measures for Victor but does not provide specific numerical values. Tom: A Christian male in his 50s with a recent diagnosis of chronic myeloid leukaemia and no prior hallucinogen use, Tom met criteria for Adjustment Disorder with Anxiety, Chronic. His session included early threatening imagery that transformed into a benign guide, strong music‑driven synesthetic experiences and a reported sense of all‑knowingness and overwhelming love. Tom reported reduced fear of death and showed moderately decreased anxiety, depression, hopelessness, demoralisation and death anxiety. His measures of religiosity and spirituality showed insignificant change, and qualitatively he reported being underwhelmed overall, describing the session as intense but not life‑changing. Chrissy: A woman in her 50s with stage 4 metastatic breast cancer and a baseline diagnosis of Generalised Anxiety Disorder, Chrissy had prior use of psilocybin and LSD. She described seeing music, a sense of being welcomed by cosmic spirits and visual motifs (stone faces returning to dust, a Ferris wheel symbolising life and death), as well as reliving her own birth and feeling an abiding connection to the cosmos. Her report emphasised unity, connection and voluntary acceptance of death alongside a decision to choose life. The extracted text reports significant decreases in anxiety, depression, death anxiety, hopelessness and demoralisation, and increases in purpose in life, spirituality and death transcendence for Chrissy. Brenda: A woman in her 60s in remission from stage I colon cancer (and previously uterine cancer) who was hallucinogen‑naïve at baseline, Brenda experienced an extended music‑guided session with sensations of being a cloud, timelessness and profound interconnectedness. She described encountering death twice in the session and emerging without fear, and the experience unearthed childhood memories of sexual assault that she identified as an opportunity to begin healing. Her data indicated decreased anxiety and death anxiety and increased spirituality. Following the trial she engaged in daily meditation and pursued activities (for example visits to a mountain monastery) to recollect elements of the experience. Across these cases the content varied widely — self‑compassion and love, acceptance of death, renewed appreciation for life and resurfacing of past trauma all recurred — but the emotional and cognitive impacts were emphasised as more easily described than episodic content. The extracted text does not provide detailed effect sizes, confidence intervals or p‑values within these case descriptions.

Ross and colleagues interpret these four cases as illustrative of the personalised and multi‑thematic nature of psilocybin‑assisted psychotherapy. They emphasise that none of the presented sessions was dominated by a single theme; instead, experiences contained multiple meaningful thematic elements while remaining idiosyncratic in content. Improvements in anxiety, depression and existential distress were sustained throughout follow‑up for these individuals regardless of the session content, suggesting that particular episodic features need not be identical across patients to yield clinical benefit. The authors note that participants often found it difficult to describe the episodic content of their sessions, and that emotional and cognitive shifts were more readily articulated than sensory or narrative detail — a phenomenon they attribute either to the ineffability of the experience or to limits of vocabulary. While prior analyses from the trial found mystical experience mediated clinical benefits, the case material here suggests additional mediators may exist; the authors propose that psilocybin may help patients gain insight into the causes of their distress, with integrative psychotherapy supporting that process. They also argue that both the pharmacological and psychotherapeutic components likely contributed to outcomes, consistent with a drug‑therapy interaction rather than a pharmacological effect alone. Several limitations and open questions are acknowledged. The cases were deliberately selected and are not intended to be generalised; the extracted text does not provide comprehensive numeric data for the main trial within these case reports. Outstanding questions for future research include whether benefit requires proximity to imminent death, the role of non‑drug methods (for example meditation) as adjuncts to maintain or re‑induce insights from the psychedelic experience, and comparative evaluation of different psychotherapeutic models (the authors contrast their "psychedelic‑peak therapy" model with historical "psychedelic‑chemotherapy" and "psycholytic" approaches). Ethical oversight for the trial was through the institutional review board at New York University School of Medicine and participants provided written informed consent.

The authors conclude that these four cases, while not generalisable, exemplify how psilocybin‑assisted psychotherapy can meet varied psychological needs through richly multi‑thematic experiences. Improvements were sustained across follow‑up and often manifested as changes in feeling, thinking and daily behaviour rather than as easily verbalised episodic recollections. Psilocybin may assist participants in attaining insight into the causes of their distress, with integrative psychotherapy important for translating acute experience into lasting benefit. The paper calls for future trials to compare psychotherapeutic models and to address unanswered questions about mediators, adjunctive non‑drug practices and optimisation of psychedelic‑assisted psychotherapy.